Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Market Cap	226.29B +7.6%
Revenue (ttm)	17.11B +53.2%
Net Income	232.18M
EPS	1.76
Shares Out	n/a
PE Ratio	974.65
Forward PE	33.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	172
Open	91.24
Previous Close	n/a
Day's Range	91.24 - 91.24
52-Week Range	67.16 - 132.40
Beta	0.35
RSI	34.30
Earnings Date	Feb 12, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1LN34

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD